ArticleCell proliferation2025
MFG-E8 Accelerates Abdominal Aortic Aneurysm Formation by Enhancing ERK MAPK/NOX4 Axis-Associated Oxidative Stress.
Article in Cell proliferation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MFG-E8 Accelerates Abdominal Aortic Aneurysm Formation by Enhancing ERK MAPK/NOX4 Axis-Associated Oxidative Stress.Cell proliferation · 2025Article
- Identification of iron metabolism-related key genes and exploration of their potential mechanisms in hemophagocytic lymphohistiocytosis based on transcriptome sequencing.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
MFG-E8 promotes oxidative stress by upregulating NOX4 and activating the MAPK pathway, which increases ROS production and affects vascular smooth muscle cell (VSMC) apoptosis, thereby driving the progression of abdominal aortic aneurysm (AAA). Resveratrol can inhibit the expression and function of MFG-E8, reduce ROS generation, and lower the incidence and severity of AAA, making it a potential therapeutic agent for AAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.